Table 3.
Women with high levels of NT-proBNP (ng/L) and hs-cTNT (ng/L)
| NTproBNP | A, (10–12 gw), n=196 | B, (20–25 gw), n=163 | C (peripartum), n=120 | D (postpartum), n=150 |
| Level >125, n (%) | 17 (9) | 13 (8) | 18 (15) | 12 (8) |
| Range>125 | 129–312 | 131–279 | 130–990 | 129–305 |
| eGFR, mean (SD) | 104 (9.7) | 106 (5.2) | 96 (14.2) | 91 (9.1) |
| Age, mean (SD) | 29 (4.8) | 29 (5.5) | 32 (5.0) | 32 (3.0) |
| BMI, median (IQR) | 23 (21–28) | 23 (21–27) | 23 (20–28) | 23 (20–29) |
| Level >300, n | 1 | 0 | 4 | 1 |
| Range>300 | 312 | n.a. | 302–990 | 305 |
| eGFR, range | 95 | n.a. | 70–91 | 83 |
| Age, range | 37 | n.a. | 26–33 | 37 |
| BMI, range | 36 | n.a. | 19–30 | 36 |
| Spontaneous vaginal delivery, n | 2 | |||
| Complication*, n | 0 | n.a. | 2 | 0 |
| C.I. post, range | 2.1 | n.a. | 1.6–3.0 | 2.1 |
| Hs-cTNT | A, n=196 | B, n=163 | C, n=119 | D, n=150 |
| Level >5.0, n (%) | 4 (2) | 1 (0.6) | 65 (55) | 3 (2) |
| Range>5.0 | 5.8–6.1 | 10.5 | 5.1–30.6 | 5.4–11.7 |
| eGFR, mean (SD) | 111 (8.6) | 105 (n.a) | 101 (10.6) | 88 (4.7) |
| Age, mean (SD) | 31 (6.4) | 37 (n.a.) | 31 (4.2) | 30 (2.1) |
| BMI, median (IQR) | 24 (23–25) | 36 (n.a) | 23 (22–28) | 24 (23–28) |
| Level >14.0, n | 0 | 0 | 3 | 0 |
| Range>14.0 | n.a. | n.a. | 14.4–30.6 | n.a. |
| eGFR, range | n.a. | n.a. | 84–103 | n.a. |
| Age, range | n.a. | n.a. | 28–37 | n.a. |
| BMI, range | n.a. | n.a. | 23–30 | n.a. |
| Spontaneous vaginal delivery, n | 3 | |||
| Complication†, n | 0 | 0 | 1 | 0 |
| CI post, range | n.a. | n.a. | 1.6–2.2 | n.a. |
*One woman with fever during delivery, one woman with pregnancy induced hypertension and postpartum haemorrhage.
†One woman with fever during delivery.
BMI, body mass index; CI post, Cardiac Index at the postpartum visit; eGFR, estimated glomerular filtration rate (mL/min/1.73) measured at the same time point as NTproBNP or hs-cTNT; gw, gestational week; hs-cTNT, high sensitive cardiac troponin T; n.a., not applicable; NTproBNP, N-terminal pro-brain natriuretic peptide.